Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This report described the case of a 70-year-old man who developed polyarthralgia after nivolumab treatment for recurrent esophageal cancer. Arthritis developed after initiating nivolumab therapy, and the patient tested positive for rheumatoid factor and anti-citrullinated peptide antibodies. The hand and elbow joints were already deformed, suggesting that he had had rheumatoid arthritis for several years and that the symptoms had only become apparent after nivolumab administration. This patient had rheumatoid arthritis, which was diagnosed as a nivolumab-induced rheumatic immune-related adverse event (rh-irAEs). Arthralgia during nivolumab administration can occur in rh-irAE cases. Patients should be assessed for autoimmune diseases before initiating immune checkpoint inhibitors.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908395PMC
http://dx.doi.org/10.2169/internalmedicine.9663-22DOI Listing

Publication Analysis

Top Keywords

rheumatoid arthritis
12
rheumatic immune-related
8
immune-related adverse
8
esophageal cancer
8
nivolumab administration
8
nivolumab
5
rheumatoid
4
arthritis symptoms
4
symptoms diagnosed
4
diagnosed rheumatic
4

Similar Publications

Background/aims: Ubiquitin D (UBD), a member of the ubiquitin-like modifier (UBL) family, is significantly overexpressed in various cancers and is positively correlated with tumor progression. However, the role and underlying mechanisms of UBD in rheumatoid arthritis (RA) remain poorly understood. This study aimed to investigate the effects of UBD knockdown on the progression of RA.

View Article and Find Full Text PDF

Expanded senescent CD8 T-cells in IMID patients are associated with distinct inflammatory cytokines.

Clin Exp Immunol

September 2025

Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.

Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).

View Article and Find Full Text PDF

Background/aims: To identify factors associated with achieving low disease activity (LDA) after 48 weeks of targeted therapy in patients with rheumatoid arthritis (RA) despite not meeting treat-to-target (T2T) criteria at week 24.

Methods: Data were collected from a multicenter, prospective observational cohort of Korea patients with RA receiving targeted therapy between April 2020 and July 2023. Patients who continued their initial targeted therapy despite not achieving LDA at week 24 were assigned to the LDA and non-LDA groups at week 48.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is an autoimmune disease typically characterized by joint pain and dysfunction. Ammopiptanthus nanus (M. Pop.

View Article and Find Full Text PDF

Effect of the combination of ion-pairs strategies and permeation enhancers on iguratimod transdermal patch against rheumatoid arthritis.

Eur J Pharm Biopharm

September 2025

Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, PR China. Electronic address:

Iguratimod (IGU) is a novel anti-rheumatic drug, which has anti-inflammatory effects, inhibits bone destruction, and promotes bone formation. However, the gastrointestinal side-effects caused by oral tablets of IGU pose a challenge. This study aimed to develop an IGU transdermal patch for Rheumatoid Arthritis (RA) through ion-pair and chemical penetrant strategies to improve the therapeutic efficacy.

View Article and Find Full Text PDF